Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Factual Report
$150.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CryoLife receives FDA approval to begin clinical trials for PerClot in the U.S


Wednesday, 2 Apr 2014 08:32am EDT 

CryoLife Inc:Receives approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration.Approval allows CryoLife to begin its pivotal clinical trial to gain approval to commercialize PerClot in the U.S. 

Company Quote

10.29
0.22 +2.18%
2:54pm EDT